Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open-label, non-randomised, prospective, single-arm trial

Richard W Laing, Hynek Mergental, Christina Yap, Amanda Kirkham, Manpreet Whilku, Darren Barton, Stuart Curbishley, Yuri L Boteon, Desley A Neil, Stefan G Hübscher, M Thamara P R Perera, Paolo Muiesan, John Isaac, Keith J Roberts, Hentie Cilliers, Simon C Afford, Darius F Mirza, Richard W Laing, Hynek Mergental, Christina Yap, Amanda Kirkham, Manpreet Whilku, Darren Barton, Stuart Curbishley, Yuri L Boteon, Desley A Neil, Stefan G Hübscher, M Thamara P R Perera, Paolo Muiesan, John Isaac, Keith J Roberts, Hentie Cilliers, Simon C Afford, Darius F Mirza

Abstract

Introduction: The use of marginal or extended criteria donor livers is increasing. These organs carry a greater risk of initial dysfunction and early failure, as well as inferior long-term outcomes. As such, many are rejected due to a perceived risk of use and use varies widely between centres. Ex situ normothermic machine perfusion of the liver (NMP-L) may enable the safe transplantation of organs that meet defined objective criteria denoting their high-risk status and are currently being declined for use by all the UK transplant centres.

Methods and analysis: Viability testing and transplantation of marginal livers is an open-label, non-randomised, prospective, single-arm trial designed to determine whether currently unused donor livers can be salvaged and safely transplanted with equivalent outcomes in terms of patient survival. The procured rejected livers must meet predefined criteria that objectively denote their marginal condition. The liver is subjected to NMP-L following a period of static cold storage. Organs metabolising lactate to ≤2.5 mmol/L within 4 hours of the perfusion commencing in combination with two or more of the following parameters-bile production, metabolism of glucose, a hepatic arterial flow rate ≥150 mL/min and a portal venous flow rate ≥500 mL/min, a pH ≥7.30 and/or maintain a homogeneous perfusion-will be considered viable and transplanted into a suitable consented recipient. The coprimary outcome measures are the success rate of NMP-L to produce a transplantable organ and 90-day patient post-transplant survival.

Ethics and dissemination: The protocol was approved by the National Research Ethics Service (London-Dulwich Research Ethics Committee, 16/LO/1056), the Medicines and Healthcare Products Regulatory Agency and is endorsed by the National Health Service Blood and Transplant Research, Innovation and Novel Technologies Advisory Group. The findings of this trial will be disseminated through national and international presentations and peer-reviewed publications.

Trial registration number: NCT02740608; Pre-results.

Keywords: hepatobiliary disease; hepatobiliary tumours; hepatology; transplant surgery.

Conflict of interest statement

Competing interests: RWL and YB receive salary as Wellcome Trust research fellows.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
Patient and donor liver pathways. HA, hepatic artery; PV, portal vein; UHB, University Hospitals Birmingham; VITTAL, Viability testing and transplantation of marginal livers.
Figure 2
Figure 2
Trial schema. VITTAL, Viability testing and transplantation of marginal livers.

References

    1. Williams R, Aspinall R, Bellis M, et al. . Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 2014;384:1953–97. 10.1016/S0140-6736(14)61838-9
    1. Williams R, Ashton K, Aspinall R, et al. . Implementation of the lancet standing commission on liver disease in the UK. Lancet 2015;386:2098–111. 10.1016/S0140-6736(15)00680-7
    1. Mathur AK, Ranney DN, Patel SP, et al. . The effect of smoking on biliary complications following liver transplantation. Transpl Int 2011;24:58–66. 10.1111/j.1432-2277.2010.01146.x
    1. NHS Blood and Transplant. Organ Donation and Transplantation Activity Report 2015/2016;16.
    1. NHS Blood and Transplant. Annual report on liver transplanation 2015/2016;16.
    1. Sotiropoulos GC, Radtke A, Molmenti EP, et al. . Long-term follow-up after right hepatectomy for adult living donation and attitudes toward the procedure. Ann Surg 2011;254:694–701. discussion 00-1 10.1097/SLA.0b013e31823594ae
    1. Simoes P, Kesar V, Ahmad J. Spectrum of biliary complications following live donor liver transplantation. World J Hepatol 2015;7:1856–65. 10.4254/wjh.v7.i14.1856
    1. Mirza DF, Gunson BK, Da Silva RF, et al. . Policies in Europe on "marginal quality" donor livers. Lancet 1994;344:1480–3. 10.1016/S0140-6736(94)90294-1
    1. NHS Blood and Transplant. Organ Donation and Transplantation Activity Report 2014/2015;15.
    1. Working Party of The British Transplantation Society. Transplantation from donors after deceased circulatory death 2013.
    1. Feng S, Goodrich NP, Bragg-Gresham JL, et al. . Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006;6:783–90. 10.1111/j.1600-6143.2006.01242.x
    1. Braat AE, Blok JJ, Putter H, et al. . The Eurotransplant donor risk index in liver transplantation: ET-DRI. Am J Transplant 2012;12:2789–96. 10.1111/j.1600-6143.2012.04195.x
    1. Belzer FO, Southard JH. Principles of solid-organ preservation by cold storage. Transplantation 1988;45:673–6. 10.1097/00007890-198804000-00001
    1. Carini R, Autelli R, Bellomo G, et al. . Alterations of cell volume regulation in the development of hepatocyte necrosis. Exp Cell Res 1999;248:280–93. 10.1006/excr.1999.4408
    1. Pratschke J, Weiss S, Neuhaus P, et al. . Review of nonimmunological causes for deteriorated graft function and graft loss after transplantation. Transpl Int 2008;21:512–22. 10.1111/j.1432-2277.2008.00643.x
    1. Menger MD, Pelikan S, Steiner D, et al. . Microvascular ischemia-reperfusion injury in striated muscle: significance of "reflow paradox". Am J Physiol 1992;263:H1901–6.
    1. Vogel T, Brockmann JG, Coussios C, et al. . The role of normothermic extracorporeal perfusion in minimizing ischemia reperfusion injury. Transplant Rev 2012;26:156–62. 10.1016/j.trre.2011.02.004
    1. Henry SD, van der Wegen P, Metselaar HJ, et al. . Hydroxyethyl starch-based preservation solutions enhance gene therapy vector delivery under hypothermic conditions. Liver Transpl 2008;14:1708–17. 10.1002/lt.21623
    1. Mediavilla MG, Krapp A, Carrillo N, et al. . Efficient cold transfection of pea ferredoxin-NADP(H) oxidoreductase into rat hepatocytes. J Gene Med 2006;8:306–13. 10.1002/jgm.847
    1. Ke B, Shen XD, Tsuchihashi S, et al. . Viral interleukin-10 gene transfer prevents liver ischemia-reperfusion injury: toll-like receptor-4 and heme oxygenase-1 signaling in innate and adaptive immunity. Hum Gene Ther 2007;18:355–66. 10.1089/hum.2007.181
    1. Le Moine O, Louis H, Demols A, et al. . Cold liver ischemia-reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice. Hepatology 2000;31:1266–74. 10.1053/jhep.2000.7881
    1. Ambiru S, Uryuhara K, Talpe S, et al. . Improved survival of orthotopic liver allograft in swine by addition of trophic factors to university of wisconsin solution. Transplantation 2004;77:302–4. 10.1097/
    1. Koti RS, Seifalian AM, Davidson BR. Protection of the liver by ischemic preconditioning: a review of mechanisms and clinical applications. Dig Surg 2003;20:383–96.
    1. Raeburn CD, Zimmerman MA, Arya J, et al. . Ischemic preconditioning: fact or fantasy? J Card Surg 2002;17:536–42. 10.1046/j.1540-8191.2002.01009.x
    1. Oniscu GC, Randle LV, Muiesan P, et al. . In situ normothermic regional perfusion for controlled donation after circulatory death-the United Kingdom experience. Am J Transplant 2014;14:2846–54. 10.1111/ajt.12927
    1. Ravikumar R, Jassem W, Mergental H, et al. . Liver transplantation after ex vivonormothermic machine preservation: a phase 1 (first-in-man) clinical trial. Am J Transplant 2016;16:1779–87. 10.1111/ajt.13708
    1. Tuttle-Newhall JE, Collins BH, Kuo PC, et al. . Organ donation and treatment of the multi-organ donor. Curr Probl Surg 2003;40:266–310. 10.1067/msg.2003.120005
    1. Frost AE. Donor criteria and evaluation. Clin Chest Med 1997;18:231–7. 10.1016/S0272-5231(05)70374-9
    1. Pirenne J, Monbaliu D, Van Gelder F, et al. . Liver transplantation using livers from septuagenarian and octogenarian donors: an underused strategy to reduce mortality on the waiting list. Transplant Proc 2005;37:1180–1. 10.1016/j.transproceed.2004.12.168
    1. Biancofiore G, Bindi M, Ghinolfi D, et al. . Octogenarian donors in liver transplantation grant an equivalent perioperative course to ideal young donors. Dig Liver Dis 2017;49:676–82. 10.1016/j.dld.2017.01.149
    1. Ferla F, De Carlis R, Mariani A, et al. . Liver transplant using octogenarian donors. Liver Transpl 2016;22:1040–1. 10.1002/lt.24450
    1. Hellinger A, Fiegen R, Lange R, et al. . Preservation of pig liver allografts after warm ischemia: normothermic perfusion versus cold storage. Langenbecks Arch Chir 1997;382:175–84. 10.1007/BF02391863
    1. Schön MR, Kollmar O, Wolf S, et al. . Liver transplantation after organ preservation with normothermic extracorporeal perfusion. Ann Surg 2001;233:114–23. 10.1097/00000658-200101000-00017
    1. Imber CJ, St Peter SD, Lopez de Cenarruzabeitia I, et al. . Advantages of normothermic perfusion over cold storage in liver preservation. Transplantation 2002;73:701–9. 10.1097/00007890-200203150-00008
    1. Butler AJ, Rees MA, Wight DG, et al. . Successful extracorporeal porcine liver perfusion for 72 hr. Transplantation 2002;73:1212–8. 10.1097/00007890-200204270-00005
    1. Brockmann J, Reddy S, Coussios C, et al. . Normothermic perfusion: a new paradigm for organ preservation. Ann Surg 2009;250:1–6. 10.1097/SLA.0b013e3181a63c10
    1. Perera T, Mergental H, Stephenson B, et al. . First human liver transplantation using a marginal allograft resuscitated by normothermic machine perfusion. Liver Transpl 2016;22:120-4 10.1002/lt.24369
    1. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1–10. 10.1016/0197-2456(89)90015-9
    1. Chen TT. Optimal three-stage designs for phase II cancer clinical trials. Stat Med 1997;16:2701–11. 10.1002/(SICI)1097-0258(19971215)16:23<2701::AID-SIM704>;2-1
    1. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–13.
    1. Dutkowski P, Oberkofler CE, Slankamenac K, et al. . Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era. Ann Surg 2011. 254 745 53:discussion 53 10.1097/SLA.0b013e3182365081
    1. NHSBT. Organ donationand transplantation. Activity report 2014/2015.
    1. Wilson EB, Inference P. The law of succession and statistical inference. JASA 1927;22:209–12.
    1. Dutkowski P, Schlegel A, Slankamenac K, et al. . The use of fatty liver grafts in modern allocation systems: risk assessment by the balance of risk (BAR) score. Ann Surg 2012. 256 861 8 discussion 68-9.
    1. NHSBT. NHSEngland Annual Report on Liver Transplantation: Report for 2015/2016. (Epub ahead of print: Sept 2016).
    1. Walker KG, Eastmond CJ, Best PV, et al. . Eosinophilia-myalgia syndrome associated with prescribed L-tryptophan. Lancet 1990;336:695–6. 10.1016/0140-6736(90)92195-N
    1. Avolio AW, Halldorson JB, Burra P, et al. . Balancing utility and need by means of donor-to-recipient matching: a challenging problem. Am J Transplant 2013;13:522–3. 10.1111/ajt.12031

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する